focus -WSS

focus

author：Wikipedia 2025-09-28 23:48:08 - browse：3918

Biogen announced a new round of cost cuts Tuesday, saying that it plans to save $700 million in operating costs and cut 1,000 jobs by 2025.

The company also released second quarter sales and earnings that handily topped the forecasts of Wall Street analysts. In early morning trading, Biogen shares rose more than 1%.

Biogen is attempting to recover from a series of corporate stumbles, the biggest of which involved the development and launch of the Alzheimer’s drug Aduhelm. The medicine was the first of a new class of disease-modifying Alzheimer’s drugs to be approved by the Food and Drug Administration. But doubts about the quality of the data behind the medicine meant that Medicare wouldn’t pay for it and doctors did not prescribe it. The resulting financial disaster cleaned out Biogen’s executive suite.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Montana youths win climate lawsuit against state for promoting fossil fuels

WSS

Should insurance cover cosmetic surgery?

Some medical students still think black patients feel less pain

Montana youths win climate lawsuit against state for promoting fossil fuels

The world needs the new pandemic treaty

Megan Rapinoe shares emotional post following US Women's World Cup exit

Illumina slashes 2023 revenue projections yet again

Wikipedia

focus

focus

In age of alternative facts, a scholarly course on calling out crap

Surge in Apellis stock fueled by confidence in safety of its eye drug

Moonlake's readout produced a cash windfall. Risks remain

Illumina slashes 2023 revenue projections yet again

Bright Health sells Medicare Advantage business to Molina

The HPV vaccine prevents cancer in men, too. Why do so few people get it?

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Why some fertility treatments produce more boy babies

23andMe had bad news about my health. I wish a person had delivered it

Louisiana bill approved classifying abortion pills as controlled substances

explore

Hospitals need to get ahead of regulations on climate change

Patients, digital health players weigh in on FTC's data privacy plan

Why some fertility treatments produce more boy babies

Louisiana bill approved classifying abortion pills as controlled substances

Patients, digital health players weigh in on FTC's data privacy plan

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

hotspot

entertainment

knowledge

focus